Lenvatinib for large hepatocellular carcinomas with portal trunk invasion: Two case reports

Figure 3 Dynamic contrast-enhanced computed tomography findings of the tumor thrombus in the main portal vein in case 2. A: Arterial-phase computed tomography (CT) image prior to the start of lenvatinib administration showing marked vascularity of the hepatocellular carcinomas, and a tumor thrombus in the main portal vein (arrows); B: Arterial-phase CT image at 4 wk after the start of lenvatinib administration showing a marked decrease of the vascularity of the hepatocellular carcinomas and decrease of the size of the tumor thrombus in the main portal vein (arrows); C: Arterial-phase CT image at 9 wk after the start of lenvatinib administration showing a continuous decrease of the vascularity of both the hepatocellular carcinomas and the size of the tumor thrombus in the main portal vein (arrows); and D: Portal-phase CT image at 9 wk after the start of lenvatinib administration showing collateral veins around the main portal vein (arrowheads).